Michael Weiswasser

机构：Bristol-Myers Squibb (United States)

发表论文 13 篇 · 总被引 130 次 · h-index 6

代表论文

• Biological impact of iberdomide in patients with active systemic lupus erythematosus (2022 · Annals of the Rheumatic Diseases · 被引 37)
• Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study (2022 · Lupus Science & Medicine · 被引 37)
• Safety of Once-Daily Ciclesonide Nasal Spray in Children 2 to 5 Years of Age with Perennial Allergic Rhinitis (2007 · Pediatric Asthma Allergy & Immunology · 被引 21)
• OP0132 EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY (2021 · Annals of the Rheumatic Diseases · 被引 8)
• Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial (2024 · Journal of the American Academy of Dermatology · 被引 7)
• SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus (2017 · Annals of the Rheumatic Diseases · 被引 6)